- Liu W et al. University of Rhode Island. Neurochem Int. 29 Sep 2016. 100: 164-177. - As part of a strategy to help guide the selection and evaluation of medicinal plant candidates for their neuroprotective potential, researchers at the University of Rhode Island developed a Neuroprotective Potential Algorithm (NPA) by evaluating twenty-three standardized and chemically characterized Ayurvedic medicinal plant extracts in a panel of bioassays targeting oxidative stress, carbonyl stress, protein glycation, amyloid beta (Aβ) fibrillation, acetylcholinesterase (AChE) inhibition, and neuroinflammation. Bacognize showed the highest in anti-Aβ fibrillation in both methods.
- Kumar et al. Evidence-Based Comp Alter Med. 2016 Sep 15. Vol 2016 (Art ID 4103423): 8pgs. DOI: 10.1155/2016/4103423 - In a randomized, placebo controlled crossover human clinical trial, administration of Bacognize® at 300mg/day to healthy medical students significantly improved (p<0.05) several parameters of cognitive function, including memory, focus, and attention. No adverse events were reported in either the Bacognize® or placebo groups.
- Headapohl et al. Effects of Bacopa monnieri (Bacognize®) on memory and cognitive function in healthy older adults: A double-blind placebo-controlled study. Manuscript. - In a randomized, placebo controlled trial in older adults, positive trends in working memory, attention, and focus were seen in the Bacognize® group (300mg/day) compared to placebo. Further, no adverse events were reported in either the Bacognize or placebo groups.
- Hingorani L et al. Planta Med. 2012. 78-PH22. DOI: 10.1055/s-0032-1320681 - In a randomized, placebo controlled trial in older adults, significant improvement in the Bacognize® group (300mg/day) was seen over placebo in short-term memory, processing speed, attention, and depression. Additionally, an effect was observed four weeks after administration discontinued. No adverse events were reported in either the Bacognize® or placebo groups.
- Goswami S et al. Int J Collab Research Internal Med. 10 May 2011. 3(4): 285-293. ISSN: 1840-4529 - Improvement in the Bacognize® group (300mg/day) was seen over placebo in areas of cognitive function in this six-month clinical trial conducted on geriatric AD subjects. No adverse events were reported in either the Bacognize® or placebo groups.
- Hall et al. Pharmacology of Bacopa monnieri (Bacognize®) at 5HT1a and 5HT2a receptors. Am Soc Pharmacog Absts. 2005. 83-85. Presented at 2005 Annual Mtg Am Soc Pharmacog, Corvallis, OR. - Pharmacology research on Bacognize and its isolated constituents showed strong regulation at serotonin receptors that are key for higher cognitive functions such as memory, mood, and focus.
- Stough et al. Phytother Res. 2008 Dec. 22(12): 1629-34.
- Calabrese et al. J Altern Complement Med. 2008 Jul. 14(6): 707-13.
- Stough et al. Psychopharmacology (Berl). 2001 Aug. 156(4): 481-4.